Docoh
Loading...

IONS Ionis Pharmaceuticals

120 patents

Page 3 of 6
APP
Utility
Modulators of APOL1 Expression
18 Mar 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
Susan M. FREIER
Filed: 18 Sep 20
APP
Utility
Modulators of PNPLA3 Expression
18 Mar 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3.
Susan M. FREIER, Huynh-Hoa BUI
Filed: 22 Jul 20
APP
Utility
Conjugated Antisense Compounds and Their Use
25 Feb 21
Provided herein are oligomeric compounds comprising a modified oligonucleotide and a conjugate group for modulating the amount or activity of a target nucleic acid in extra hepatic tissues and extra hepatic cells.
Thazha P. Prakash, Richard Lee, Punit P. Seth, Eric E. Swayze, Frank Rigo, Michael Oestergaard
Filed: 26 Sep 16
APP
Utility
Conjugated Antisense Compounds and Their Use
25 Feb 21
Provided herein are oligomeric compounds with conjugate groups.
Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
Filed: 24 Feb 20
APP
Utility
Compounds and Methods for Modulating Gfap
11 Feb 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of GFAP RNA in a cell or subject, and in certain instances reducing the amount of GFAP in a cell or subject.
Berit Elissa Powers, Huynh-Hoa Bui, Susan M. Freier, Frank Rigo
Filed: 24 Jul 20
APP
Utility
Modulators of IRF4 Expression
11 Feb 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
Tianyuan Zhou, Youngsoo Kim, Robert MacLeod, Huynh-Hoa Bui, Susan M. Freier
Filed: 1 Mar 19
APP
Utility
Compounds and Methods for the Modulation of Amyloid-beta Precursor Protein
11 Feb 21
Certain embodiments disclosed herein are directed to compounds and methods for modulating APP expression.
Frank Rigo, Michelle Hastings
Filed: 1 Mar 19
APP
Utility
Compositions and Methods for Modulating TTR Expression
28 Jan 21
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 13 Feb 20
APP
Utility
Modified Compounds and Uses Thereof
21 Jan 21
The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications.
Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
Filed: 12 Feb 19
APP
Utility
Compositions and Their Uses Directed to Huntingtin
21 Jan 21
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
Filed: 10 Aug 20
APP
Utility
Modulation of HSD17B13 Expression
6 Jan 21
Provided herein are methods, compounds, and compositions for reducing expression of HSD17B13 in a cell or individual.
Susan F. Murray, Jiangwei Zhang, Huynh-Hoa Bui
Filed: 20 Mar 19
APP
Utility
Selective Antisense Compounds and Uses Thereof
6 Jan 21
The present invention provides oligomeric compounds.
Michael Oestergaard, Punit P. Seth, Eric E. Swayze
Filed: 17 Feb 20
APP
Utility
Methods and Compositions for Modulating Apolipoprotein (A) Expression
6 Jan 21
Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a).
Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
Filed: 2 Aug 20
APP
Utility
Methods for Modulating FMR1 Expression
6 Jan 21
Provided are methods for increasing the amount or activity of FMR1 RNA, and in certain instances of increasing the amount of FMRP protein, in an animal Such methods are useful to prevent or ameliorate at least one symptom of a Fragile X-Spectrum disorder.
Frank RIGO, Peter TODD, Caitlin RODRIGUEZ
Filed: 21 Mar 19
APP
Utility
Methods of Modulating Antisense Activity
30 Dec 20
Disclosed herein are methods for increasing antisense activity by modulating EGFR.
Shiyu Wang, Alexey Revenko, Xue-hai Liang, Stanley T. Crooke
Filed: 12 Feb 19
APP
Utility
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
16 Dec 20
The present invention provides oligomeric compounds.
Susan M. Freier, Eric E. Swayze
Filed: 20 Jan 20
APP
Utility
Compounds and Methods for Reducing Snca Expression
16 Dec 20
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal.
Holly Kordasiewicz, Priyam Singh, Susan M. Freier, Tracy A. Cole
Filed: 8 Nov 18
APP
Utility
Conjugated Antisense Compounds and Their Use
16 Dec 20
The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound.
Michael Oestergaard, Punit P. Seth, Frank Rigo, Chrissa A. Dwyer
Filed: 13 Dec 18
APP
Utility
Modulators of DNM2 Expression
16 Dec 20
The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
Susan M. FREIER, Huynh-Hoa BUI, Susan F. MURRAY, Brett P. MONIA, Shuling GUO
Filed: 14 Jan 19
APP
Utility
5' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
9 Dec 20
The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 29 Apr 20
Patents are sorted by USPTO publication date, most recent first